NeOnc Technologies develops drug candidates for brain cancers, including NEO100 and NEO212, which are still in clinical trials. NTHI reports earnings on Thu, Nov 12, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 24 | Roth Capital | Initiated | Buy | |
| Sep 8 | BTIG | Reiterated | Buy | |
| May 19 | Alliance Global Partners | Initiated | Buy | |
| May 18 | Maxim Group | Initiated | Buy | |
| Apr 24 | BTIG | Initiated | Buy |
Whale Options Flow
90DNo whale options trades in NTHI in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NTHI is in one of them and how their past NTHI trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered NTHI in an article yet. Here's the latest on the wider market.
About Neonc Technologies Holdings
NeOnc Technologies develops drugs for cancers that start in the brain or spread there, including glioblastoma, meningioma and brain metastases from lung, breast and skin cancers. Its lead candidates are NEO100, a purified form of perillyl alcohol given by nasal spray, and NEO212, an oral drug that combines temozolomide with perillyl alcohol. The company has no approved products yet and is testing its candidates in trials with patients who have brain tumors. It is based in Calabasas, California.
- Headquarters
- Calabasas, CA